Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1649989/000114420418029003/tv493343_10q.htm
SEC Filings
ONS Annual Reports
ONS Quarterly Reports
ONS Corporate News
Financial Exhibit
New Agreement
New Financial Obligation
Other Events
Security Holders Change
Unregistered Sales November 2018
Listing Status October 2018
Event for Officers
Financial Exhibit October 2018
Event for Officers
Financial Exhibit
Vote of Security Holders September 2018
Ending Agreement September 2018
Earnings Release
Financial Exhibit August 2018
Event for Officers
Financial Exhibit
Other Events August 2018
Bylaw Change
Financial Exhibit
New Agreement
Other Events
Security Holders Change
Unregistered Sales
Vote of Security Holders July 2018
Financial Exhibit
Other Events July 2018
Event for Officers July 2018
Financial Exhibit
New Agreement
New Financial Obligation
Other Events
Security Holders Change
Unregistered Sales
New Agreement
New Financial Obligation
Other Events
Security Holders Change
Unregistered Sales
November 2018
Listing Status
October 2018
Event for Officers
Financial Exhibit
Financial Exhibit
October 2018
Event for Officers
Financial Exhibit
Vote of Security Holders
Financial Exhibit
Vote of Security Holders
September 2018
Ending Agreement
September 2018
Earnings Release
Financial Exhibit
Financial Exhibit
August 2018
Event for Officers
Financial Exhibit
Other Events
Financial Exhibit
Other Events
August 2018
Bylaw Change
Financial Exhibit
New Agreement
Other Events
Security Holders Change
Unregistered Sales
Vote of Security Holders
Financial Exhibit
New Agreement
Other Events
Security Holders Change
Unregistered Sales
Vote of Security Holders
July 2018
Financial Exhibit
Other Events
Other Events
July 2018
Event for Officers
July 2018
Last10K.com | 10-Q Quarterly Report Tue May 15 2018
Exhibit 99.1
News Release
Oncobiologics Reports Second Quarter Financial Results for Fiscal 2018
Cranbury, NJ – May 15, 2018 — Oncobiologics, Inc. (NASDAQ: ONS) today reported financial results and business highlights for its three and six months ended March 31, 2018.
Recent Highlights:
| · | Strengthened balance sheet with first closing of a $15.0 million private placement offering |
| · | Initiated ONS-5010 development program |
| · | Appointed Dr. Joerg Windisch and Randy Thurman to the Board of Directors |
| o | Dr. Windisch was appointed to the Compensation Committee |
| o | Mr. Thurman was appointed to the Nominating and Corporate Governance Committee and Chairman of the Compensation Committee |
Oncobiologics’ Chairman and Chief Executive Officer Dr. Pankaj Mohan commented, “I am excited to report that our pipeline continues to offer significant opportunities to generate stockholder value. We recently entered into an agreement for a $15.0 million capital raise that will be used to advance the development of our portfolio, including ONS-5010, and support our operations through the end of this calendar year and have already received $7.5 million of the proceeds.
“We continue to make progress with the ONS-5010 development program and expect to initiate a clinical trial in 2018. Additionally, we are advancing our pre-clinical biosimilar product candidates and continue to engage with potential partners to lead the Phase 3 clinical trials for ONS-3010 and ONS-1045,” continued Dr. Mohan.
“During the second quarter of fiscal 2018, we made progress implementing our new strategy to leverage our BioSymphony Platform to accelerate and maximize commercial revenues from our core expertise in drug development and manufacturing. The interest in leveraging our extensive development and manufacturing platform among potential biotech customers has been extremely positive. We expect to enter into our first customer agreement for our new contract development and manufacturing (CDMO) business and start recognizing revenue in the near future,” concluded Dr. Mohan.
Anticipated Milestones (calendar year):
2018
| · | Enter into first CDMO contract |
| · | Initiate clinical development program for ONS-3010 and/or ONS-1045 by partners in emerging markets |
| · | Initiate ONS-5010 clinical trials |
| · | Announce licensing/co-development partnership |
The following information was filed by Oncobiologics, Inc. (ONS) on Tuesday, May 15, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Oncobiologics, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Oncobiologics, Inc..
Assess how Oncobiologics, Inc.'s management team is paid from their Annual Proxy
Oncobiologics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Rating
Learn More
Filter Sentiment:
Filter Category:
Filter Subcategory:
-
Revenue - Product Highlight
On May 14, 2018, we closed the sale of the first tranche of the common stock and warrants for aggregate cash proceeds of $7.5 million, issuing to GMS Tenshi an aggregate of 6,377,383 shares of our common stock and warrants to acquire up to 10,256,410 additional shares of our common stock at an exercise price of $0.975 per share, which warrants have a term of eight years from their issuance date.
-
Financial - Expense Highlight
Research and development expenses for the six months ended March 31, 2018 decreased by $11.8 million compared to the six months ended March 31, 2017 due to reductions in pre-clinical and clinical development spending, a related contract settlement and lower personnel related costs.
-
Financial - Expense Highlight
This resulted in a $7.5 million decrease in costs related to these two programs, which was partially offset by almost $2.0 million in development costs incurred related to our new ONS-5010 program as we prepare for clinical trials in 2018.
-
Financial - Expense Highlight
We anticipate that our general and administrative expenses will increase as a result of increased payroll, expanded infrastructure and an increase in accounting, consulting, legal and tax-related services associated with maintaining compliance with stock exchange listing and SEC requirements, investor relations costs, and director and officer insurance premiums associated with being a public company.
-
Financial - Expense Highlight
We expect our research and development expenses to increase significantly over the next several years as we increase personnel costs, including stock-based compensation, conduct clinical trials and prepare regulatory filings for our product candidates.
-
Revenue - Product
The change in our operating...Read more
-
Financial - Expense
During the six months ended...Read more
-
Financial - Expense
Other general and administrative expenses...Read more
-
Financial - Expense
Interest expense decreased by $0.3...Read more
-
Financial - Expense
Interest expense decreased by $0.1...Read more
-
Financial - Cash Flow
We have incurred operating losses...Read more
-
Other - Other
For example, if the U.S....Read more
-
Financial - Shares
We plan to finance our...Read more
-
Financial - Income
There is also a risk...Read more
-
Financial - Shares
These strategies may include, but...Read more
-
Financial - Expense
General and administrative expenses for...Read more
-
Financial - Expense
General and administrative expenses for...Read more
-
Revenue - Product
Through March 31, 2018, we...Read more
-
Financial - Expense
The increase in research and...Read more
-
Revenue - Product
Collaboration revenues increased $0.9 million,...Read more
-
Revenue - Product
Collaboration revenues increased $0.5 million,...Read more
-
Other - Other
We determined that there are...Read more
-
Financial - Expense
We also anticipate that our...Read more
-
Financial - Expense
We believe that this strategy...Read more
-
Revenue - Product
We determined that the upfront...Read more
-
Revenue - Product
In conjunction with the strategic...Read more
-
Financial - Cash Flow
Since inception, we have incurred...Read more
-
Financial - Cash Flow
We have incurred recurring losses...Read more
-
Financial - Expense
Research and development expenses for...Read more
-
Other - Other
In January 2014, we entered...Read more
-
Revenue - Product
Until we begin generating revenue...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parentheticals)
Consolidated Statements Of Cash Flows (unaudited)
Consolidated Statements Of Convertible Preferred Stock And Stockholders' Equity (deficit) (unaudited)
Consolidated Statements Of Operations (unaudited)
Accrued Expenses
Accrued Expenses (details)
Accrued Expenses (tables)
Basis Of Presentation And Summary Of Significant Accounting Policies
Basis Of Presentation And Summary Of Significant Accounting Policies (detail Textuals 1)
Basis Of Presentation And Summary Of Significant Accounting Policies (detail Textuals)
Basis Of Presentation And Summary Of Significant Accounting Policies (details 1)
Basis Of Presentation And Summary Of Significant Accounting Policies (details)
Basis Of Presentation And Summary Of Significant Accounting Policies (policies)
Basis Of Presentation And Summary Of Significant Accounting Policies (tables)
Commitments
Commitments (detail Textuals)
Commitments (details)
Commitments (tables)
Convertible Preferred Stock And Stockholders' Equity (deficit)
Convertible Preferred Stock And Stockholders' Equity (deficit) (detail Textuals)
Convertible Preferred Stock And Stockholders' Equity (deficit) (details)
Convertible Preferred Stock And Stockholders' Equity (deficit) (tables)
Fair Value Measurements
Fair Value Measurements (details 1)
Fair Value Measurements (details 2)
Fair Value Measurements (details)
Fair Value Measurements (tables)
Liquidity
Liquidity (detail Textuals)
Organization And Description Of Business
Property And Equipment, Net
Property And Equipment, Net (detail Textuals)
Property And Equipment, Net (details)
Property And Equipment, Net (tables)
Senior Secured Notes
Senior Secured Notes (detail Textuals)
Senior Secured Notes (details)
Senior Secured Notes (tables)
Stock Based Compensation (detail Textuals 1)
Stock Based Compensation (detail Textuals 2)
Stock Based Compensation (detail Textuals)
Stock Based Compensation (details 1)
Stock Based Compensation (details 2)
Stock Based Compensation (details 3)
Stock Based Compensation (details 4)
Stock Based Compensation (details)
Stock-based Compensation
Stock-based Compensation (tables)
Subsequent Events
Subsequent Events (detail Textuals)
Material Contracts, Statements, Certifications & more
Oncobiologics, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ONS
CIK: 1649989
Form Type: 10-Q Quarterly Report
Accession Number: 0001144204-18-029003
Submitted to the SEC: Tue May 15 2018 5:16:26 PM EST
Accepted by the SEC: Tue May 15 2018
Period: Saturday, March 31, 2018
Industry: Biological Products No Disgnostic Substances
External Resources:
Stock Quote
Social Media
Bookmark the Permalink: https://last10k.com/sec-filings/ons/0001144204-18-029003.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...